Drug intelligence / Profile preview

Reparagen

Development stage: Unknown
Lead developer: Rainforest Naturals
Administration: Oral

Overview

Reparagen is a dietary supplement developed by Sanifortpharma, a Belgian manufacturer specializing in nutritional products. The supplement is specifically formulated to support joint health, flexibility, and the maintenance of cartilage quality. Its active composition includes glucosamine, which serves as a structural building block for joint cartilage; curcumin (derived from turmeric), which provides antioxidant support and aids in maintaining joint mobility; and *Arthrospira platensis* (spirulina), which contains phycocyanin for anti-inflammatory benefits. Reparagen is administered orally and is marketed toward individuals experiencing joint wear or those seeking to maintain joint shock absorption, including athletes.

Brand names: Reparagen

Targets

IGF-1 (Insulin-like growth factor 1)

Beyond the preview

Go deeper on Reparagen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reparagen.

Explore the full profile